Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment crawled date : 2021 - 05 - 25 save search
Moleculin Commences Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Sarcoma Lung Metastases
Published: 2021-05-25 (Crawled : 14:00) - biospace.com/
MBRX | News | $4.59 7.24% 6.75% 50K
|
Health Technology
|
| O: 1.94%
H: 0.27%
C: -3.26%
treatment phase 1 trial phase 1b phase 2b
Eyenovia Announces Positive Topline Results from VISION-1 Phase 3 Clinical Study of MicroLine for the Treatment of Presbyopia
Published: 2021-05-25 (Crawled : 13:15) - globenewswire.com
EYEN | $0.5385 -0.15% -0.15% 570K
|
Health Technology
|
| O: 13.32%
H: 17.16%
C: -9.86%
treatment eye positive results topline phase 3 presbyopia
Psychedelic Drug Market Has Become a Billion Dollar Industry As Acceptable Treatments Expand
Published: 2021-05-25 (Crawled : 13:00) - prnewswire.com
MNMD | $8.92 -6.4% -6.84% 1.6M
|
n/a
|
| O: 3.09%
H: 0.3%
C: -4.49%
CMPS | $8.41 -1.41% -1.43% 290K
|
Health Technology
|
| O: -0.06%
H: 1.12%
C: -5.56%
treatment drug
DUPIXENT® (dupilumab injection) now publicly reimbursed in Ontario and New Brunswick for the treatment of moderate-to-severe atopic dermatitis
Published: 2021-05-25 (Crawled : 12:00) - biospace.com/
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.71%
H: 0.0%
C: -0.63%
treatment injection dermatitis atopic dermatitis dupixent
TG Therapeutics Announces FDA Acceptance of Biologics License Application for Ublituximab in Combination with UKONIQ® (umbralisib) as a Treatment for Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Published: 2021-05-25 (Crawled : 12:00) - biospace.com/
TGTX | News | $14.0 1.3% 1.29% 3.5M
|
Health Technology
|
| O: 3.05%
H: 1.99%
C: -3.51%
treatment fda fda acceptance license leukemia
Apellis and Sobi Report Positive Top-line Results from the Phase 3 PRINCE Study of EMPAVELI™ (pegcetacoplan) in Treatment-naïve Patients with PNH
Published: 2021-05-25 (Crawled : 12:00) - biospace.com/
APLS | $47.51 -1.08% -1.09% 1.9M
|
Health Technology
|
| O: 2.31%
H: 3.23%
C: 0.02%
treatment positive results phase 3 topline
Positive top-line results from the phase 3 PRINCE study of pegcetacoplan in treatment-naïve patients with PNH
Published: 2021-05-25 (Crawled : 12:00) - biospace.com/
APLS | $47.51 -1.08% -1.09% 1.9M
|
Health Technology
|
| O: 2.31%
H: 3.23%
C: 0.02%
treatment positive results phase 3 topline
EyePoint Pharmaceuticals Announces Completion of Enrollment of Phase 1 DAVIO Clinical Trial of EYP-1901 for the Potential Treatment of Wet AMD
Published: 2021-05-25 (Crawled : 12:00) - biospace.com/
EYPT | $17.49 -16.48% -19.73% 4.1M
|
Health Technology
|
| O: 0.77%
H: 1.85%
C: -1.3%
treatment eye phase 1 potential trial phase 3 phase 2 dmd enroll
European Commission approves Ponvory (ponesimod) for the treatment of adults with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features
Published: 2021-05-25 (Crawled : 06:00) - globenewswire.com
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: 0.07%
H: 0.21%
C: -0.35%
multiple sclerosis disease treatment europe sclerosis imaging
Innovent Announces First Patient Dosed in China in the Global Phase 3 Clinical Trial of Pemigatinib as the First-line Treatment of Unresectable or Metastatic Cholangiocarcinoma
Published: 2021-05-25 (Crawled : 01:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.2%
H: 0.21%
C: -1.1%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: 0.06%
H: 0.98%
C: -0.34%
treatment china phase 3 trial
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.